Hematology

The addition of daratumumab to standard treatment of lenalidomide and dexamethasone for patients with multiple myeloma, who were ineligible for autologous stem-cell transplant, was found to significantly lower the risk of disease progression or death compared with those who only received standard treatment.

According to results from a recent retrospective study, patients previously diagnosed with a hematologic malignancy were found to be at a higher risk of developing head and neck cancers compared with patients without a prior hematologic malignancy.

Analysis of findings from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study found no association between sickle cell trait and cognitive impairment.

As a precursor to myeloma, smoldering multiple myeloma (MM) currently has no treatment. In fact, the standard of care is observation until the patient starts to present with symptoms. However, according to new research that will be presented at the American Society of Clinical Oncology’s annual meeting in Chicago, Illinois, held May 31 to June 4, early treatment of smoldering MM may delay progression to full-blown disease.

Venetoclax (Venclexta) has received FDA approval in combination with obinutuzumab (Gazyva) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), offering a chemotherapy-free regimen for patients with previously untreated disease.

Cure rates for Hodgkin lymphoma are high, but survivors may live for decades with side effects from chemotherapy. Finding a new treatment target could lead to fewer toxic effects.

Researchers have identified a new target in the mitochondria of cancer cells that indicate the potential of a treatment class for certain blood cancers.

Proof-of-concept studies suggest the treatment that targets CD47 produces a strong response in patients with diffuse large B-cell lymphoma (DLBCL) with fewer adverse effects than current options.

DNA rearrangement may be the key to predicting poor outcomes in high-risk patients with multiple myeloma, according to a new study.

Radiotherapy after chemotherapy is controversial, as evidenced by the fact that doctors for some patients in the study did not follow the protocol for those assigned to radiotherapy and may have affected the results.

Modifications to the engineering of the chimeric antigen receptor (CAR) mean that the patient produces fewer cytokines and has time to clear them before they build up in the bloodstream.

As part of CMS’ FY 2020 Medicare Hospital Inpatient Prospective Payment System and Long-Term Acute Care Hospital Prospective Payment System Proposed Rule and Request for Information, the agency is proposing an increase in how much it reimburses hospitals for chimeric antigen receptor (CAR) T-cell therapy, as well as wage index hikes for rural hospitals.

The investment fund spun off from the Multiple Myeloma Research Foundation will start at $50 million and will be self-sustaining, focusing on early-stage biotech companies.

Among patients with multiple myeloma treated with older proteasome inhibitors, those who developed peripheral neuropathy (PN) had significantly higher costs, suggesting that newer therapies may maintain effective treatment while lowering the economic and disease burden of PN in these patients.

A preliminary study discussed how a vaccine regimen stimulated dendritic cells to attack tumors, which could point to a new way of making immunotherapy effective in cancers that have proved resistant to treatment thus far.

Assessing 4 dose levels of carfilzomib, researchers have determined that the drug, in combination with thalidomide and low-dose dexamethasone, is highly safe and effective in transplant-eligible patients with newly diagnosed multiple myeloma.

Step therapy, which requires that patients try the payer’s preferred treatment before the one a physician recommends, is harmful to both sides of the doctor-patient relationship, according to Lee B. Schwartzberg, MD, medical director of the West Cancer and Research Institute, who spoke at the 2019 Community Oncology Conference, held in Orlando, Florida.

A study of patients with multiple myeloma in a real-world setting found that adherence to immunomodulatory drugs (IMIDs) is high across all 3 options of the drugs.

A comprehensive genomic analysis of acute erythoid leukemia (AEL) found that 45% of patients had mutations in signaling pathways that drive uncontrolled cell growth, and evidence shows these leukemias may respond to existing precision treatments.

A study consisting of interviews and focus groups among patients with relapsed or refractory multiple myeloma brought attention to what patients value about their treatment.

This week, the FDA sent out an alert to various healthcare professionals and the public to warn about the risks associated with the investigational use of venetoclax (Venclexta) for the treatment of patients with multiple myeloma (MM). The alert is based on data from the ongoing phase 3 BELLINI trial evaluating the drug for this treatment.

A panel during the opening day of the 2019 National Comprehensive Cancer Network Annual Conference examined the recent process for National Coverage Determination for chimeric antigen receptor (CAR) T-cell therapy and what it means for the future of innovative treatments.

There is concern among stakeholder groups that references to “hospital” could mean that community practices would be unable to be reimbursed by Medicare under a proposed National Coverage Determination.

Pooled data from 2 studies revealed that once-weekly administration of 70 mg/m2 of carfilzomib is as safe and effective in newly diagnosed multiple myeloma (MM) as twice-weekly administration of 36 mg/m2 of the treatment while also providing a more convenient treatment schedule.

While use of palliative care at the end of life has increased, disparities remain, and not all patients who are terminally ill with blood cancers are having discussions about their goals of care at the end of life.